The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial
Lancet Psychiatry
Fecha de publicación: 12 october 2018
DOI: https://doi.org/10.1016/S2215-0366(18)30345-6
Autores: Prof Bill Deakin, FMedSci., John Suckling, PhD., Thomas R E Barnes, DSc., Kelly Byrne, BA., Imran B Chaudhry, MD., Paola Dazzan, PhD., et al.
Background: The antibiotic minocycline has neuroprotective and anti-inflammatory properties that could prevent or reverse progressive neuropathic changes implicated in recent-onset schizophrenia. In the BeneMin study, we aimed to replicate the benefit of minocycline on negative symptoms reported in previous pilot studies, and to understand the mechanisms involved.
